SABR could defer systemic therapy in oligoprogressive breast cancer
“We found surprisingly that SABR delayed a change in therapy by 10 months, which is great for patients.”
Related Articles
Adding Life to Your Patients’ Years
Physician discusses how to help older patients live well, not just longer.
The Obesogenic Environment of Preschool and Day Care | MDedge
Our challenge is to create effective, yet sensitive, strategies to help the educators and caregivers modify their dietary habits behaviors in a way that helps…
Approved Therapy for ALS Is Withdrawn When New Study Shows No Benefit | MDedge
Unlike a first trial of PB&TURSO, which led to regulatory approval of this combination therapy in 2022, a second larger and longer multicenter placebo-controlle
Vaccination regimen effective in preventing pneumonia in MM patients | MDedge
Vaccination was effective despite the expected decrease in immunological response during target and immunotherapy.
Are Women Better Doctors Than Men? | MDedge
Female patients had a significantly lower 30-day mortality rate than male patients, but they fared even better when cared for by female doctors compared with…
Getting Patients With Opioid Use Disorder Started on Buprenorphine in Primary Care
Any DEA-registered PCP can prescribe buprenorphine and should screen for opioid use disorder, presenter says.
Federal Trade Commission Bans Noncompete Agreements, Urges More Protections for Healthcare Workers
But dissenting commissioners dispute the FTC’s authority to broadly ban noncompetes.
Could Modifying Gut Microbiota Enhance Response to Methotrexate in RA?
Investigators have found evidence suggesting that bad bugs in the belly may contribute to inflammation in the joints, and that modulating gut microbes could improve…
Physicians Own Less Than Half of US Practices; Federal Agencies Want Outside Input
A new report on trends in medical practice ownership came amid increased federal scrutiny of consolidation and the role of private equity.